Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target

Current Pharmaceutical Design

Volumn 18, Issue 20, 2012, Pages 2883-2890

  Kryštof, Vladimír ^a   Baumli, Sonja ^b   Fürst, Robert ^c  

^a INSTITUTE OF EXPERIMENTAL BOTANY   (Czech Republic)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiogenesis; Cancer; Inflammation; Inhibitor; Kinase; P TEFb; Therapeutics

Indexed keywords

4 (4 HYDROXYPHENYL)AZO 3,5 DIAMINO 1H PYRAZOLE; 4 AMINO 6 HYDRAZINO 7 BETA DEXTRO RIBOFURANOSYL 7H PYRROLO[2,3 D]PYRIMIDINE 5 CARBOXAMIDE; ADENOSINE TRIPHOSPHATE; ANDROGEN RECEPTOR; ANGIOGENESIS INHIBITOR; AT 7519; CAN 508; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; DNA; FLAVOPIRIDOL; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PROTEIN MCL 1; ROSCOVITINE; STAT3 PROTEIN; TG 02; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; VER 5405; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BINDING SITE; CANCER CELL; CANCER THERAPY; CELL CYCLE; CELL DEATH; CELL TYPE; CHEMICAL STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; DNA CONTENT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; INFLAMMATION; NEUROBLASTOMA CELL; NONHUMAN; OSTEOSARCOMA CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 84861728358     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800672750     Document Type: Review

References (88)

1. Loyer P, Trembley JH, Katona R, Kidd VJ, Lahti JM. Role of CDK/cyclin complexes in transcription and RNA splicing. Cell Signal 2005; 17: 1033-51.
2. Yu DS, Cortez D. A role for cdk9-cyclin k in maintaining genome integrity. Cell Cycle 2011; 10: 28-32.
3. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30: 630-41.
4. Romano G, Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle 2008; 7: 3664-8.
5. Nechaev S, Adelman K. Pol II waiting in the starting gates: Regulating the transition from transcription initiation into productive elongation. Biochim Biophys Acta 2011; 1809: 34-45.
6. Wada T, Takagi T, Yamaguchi Y, Watanabe D, Handa H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. EMBO J 1998; 17: 7395-403.
7. Rahl PB, Lin CY, Seila AC, et al. c-Myc regulates transcriptional pause release. Cell 2010; 141: 432-45.
8. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. NF-kappa B binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001; 8: 327-37.
9. Lee DK, Duan HO, Chang CS. Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation. J Biol Chem 2001; 276: 9978-84.
10. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 2005; 19: 523-34.
11. Yang Z, Yik JH, Chen R, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 2005; 19: 535-45.
12. Sobhian B, Laguette N, Yatim A, et al. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol Cell 2010; 38: 439-51.
13. Lin C, Smith ER, Takahashi H, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010; 37: 429-37.
14. Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007; 110: 4445-54.
15. Yang Z, Zhu Q, Luo K, Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 2001; 414: 317-22.
16. Michels AA, Nguyen VT, Fraldi A, et al. MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcriptiondependent manner. Mol Cell Biol 2003; 23: 4859-69.
17. Krueger BJ, Jeronimo C, Roy BB, et al. LARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associated. Nucleic Acids Res 2008; 36: 2219-29.
18. Fisher RP. Secrets of a double agent: CDK7 in cell-cycle control and transcription. J Cell Sci 2005; 118: 5171-80.
19. Bartkowiak B, Liu PD, et al. CDK12 is a transcription elongationassociated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev 2010; 24: 2303-16.
20. Blazek D, Kohoutek J, Bartholomeeusen K, et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 2011; 25: 2158-72.
21. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-66.
22. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 8: 547-66.
23. Krystof V, Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 2010; 11: 291-302.
24. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 276: 31793-9.
25. Cai D, Latham VM, Jr., Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 2006; 66: 9270-80.
26. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002; 8: 3527-38.
27. MacCallum DE, Melville J, Frame S, et al. Seliciclib (CYC202, RRoscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005; 65: 5399-407.
28. Raje N, Kumar S, Hideshima T, et al. Seliciclib (CYC202 or Rroscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005; 106: 1042-7.
29. Santo L, Vallet S, Hideshima T, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010; 29: 2325-36.
30. Krystof V, Chamrad I, Jorda R, Kohoutek J. Pharmacological targeting of CDK9 in cardiac hypertrophy. Med Res Rev 2010; 30: 646-66.
31. Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 2008; 29: 302-13.
32. Brown NR, Noble MEM, Endicott JA, Johnson LN. The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat Cell Biol 1999; 1: 438-43.
33. Baumli S, Lolli G, Lowe ED, et al. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J 2008; 27: 1907-18.
34. Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 2010; 465: 747-U2.
35. Eswaran J, Knapp S. Insights into protein kinase regulation and inhibition by large scale structural comparison. Biochim Biophys Acta 2010; 1804: 429-32.
36. Bettayeb K, Baunbaek D, Delehouze C, et al. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer 2010; 1: 369-80.
37. Baumli S, Endicott JA, Johnson LN. Halogen Bonds Form the Basis for Selective P-TEFb Inhibition by DRB. Chem Biol 2010; 17: 931-6.
38. de Azevedo WFJ, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996; 93: 2735-40.
39. Bettayeb K, Oumata N, Echalier A, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008; 27: 5797-807.
40. Vedadi M, Niesen FH, Allali-Hassani A, et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc Natl Acad Sci USA 2006; 103: 15835-40.
41. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16: 120-7.
42. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56: 2973-8.
43. Squires MS, Feltell RE, Wallis NG, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclindependent kinases, in human tumor cell lines. Mol Cancer Ther 2009; 8: 324-32.
44. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001; 2: RESEARCH0041.
45. Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106: 2513-9.
46. Chen R, Wierda WG, Benaissa S, et al. Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol. Blood 2009; 110: 915A.
47. Hahntow IN, Schneller F, Oelsner M, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004; 18: 747-55.
48. Bettayeb K, Baunbaek D, Delehouze C, et al. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer 2010; 1: 369-80.
49. Scrace SF, Kierstan P, Borgognoni J, et al. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked. Cell Cycle 2008; 7: 3898-907.
50. Ambrosini G, Seelman SL, Qin LX, Schwartz GK. The cyclindependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res 2008; 68: 2312-20.
51. Shah MA, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005; 11: 3836-45.
52. Mueller D, Bach C, Zeisig D, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007; 110: 4445-54.
53. Frame S, Hogben M, Munro C, Blake DG, Green SR, Zheleva DI. Therapeutic potential of CDK inhibitors in MLL leukemias. Proceedings of the American Association for Cancer Research Annual Meeting; 201 Apr 17-21; Washington, DC, USA. Amer Assoc Canc Res 2010; p. 945.
54. Goh KC, Novotny-Diermayr V, Hart S, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent antileukemic properties. Leukemia 2011.
55. Gordon V, Bhadel S, Wunderlich W, et al. CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation. Mol Endocrinol 2010; 24: 2267-80.
56. Ali MA, Choy H, Habib AA, Saha D. SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 2007; 9: 370-81.
57. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, downregulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999; 59: 5433-7.
58. Radhakrishnan SK, Gartel AL. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res 2006; 66: 3264-70.
59. Stockwin LH, Yu SX, Stotler H, Hollingshead MG, Newton DL. ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC Cancer 2009; 9: 63.
60. Liebl J, Weitensteiner SB, Vereb G, et al. Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J Biol Chem 2010; 285: 35932-43.
61. Krystof V, Cankar P, Frysova I, et al. 4-arylazo-3,5-diamino-1Hpyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem 2006; 49: 6500-9.
62. Krystof V, Rarova L, Liebl J, et al. The selective P-TEFb inhibitor CAN508 targets angiogenesis. Eur J Med Chem 2011; 46: 4289-94.
63. Ogba N, Doughman YQ, Chaplin LJ, et al. HEXIM1 modulates vascular endothelial growth factor expression and function in breast epithelial cells and mammary gland. Oncogene 2010; 29: 3639-49.
64. Zahler S, Liebl J, Furst R, Vollmar AM. Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro. Angiogenesis 2010; 13: 239-49.
65. Kohoutek J, Li QT, Blazek D, Luo ZP, Jiang HM, Peterlin BM. Cyclin T2 Is Essential for Mouse Embryogenesis. Mol Cell Biol 2009; 29: 3280-5.
66. Shim EY, Walker AK, Shi Y, Blackwell TK. CDK-9/cyclin T (PTEFb) is required in two postinitiation pathways for transcription in the C-elegans embryo. Genes Dev 2002; 16: 2135-46.
67. Eissenberg JC, Shilatifard A, Dorokhov N, Michener DE. Cdk9 is an essential kinase in Drosophila that is required for heat shock gene expression, histone methylation and elongation factor recruitment. Mol Genet Genomics 2007; 277: 101-14.
68. Sekine C, Sugihara T, Miyake S, et al. Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclindependent kinase inhibitors. Journal of Immunology 2008; 180: 1954-61.
69. Schmerwitz UK, Sass G, Khandoga AG, et al. Flavopiridol Protects Against Inflammation by Attenuating Leukocyte-Endothelial Interaction via Inhibition of Cyclin-Dependent Kinase 9. Arterioscler Thromb Vasc Biol 2011; 31: 280-U121.
70. Berberich N, Uhl B, Joore J, et al. Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9. Br J Pharmacol 2011; 163: 1086-98.
71. Arguello F, Alexander M, Sterry JA, et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998; 91: 2482-90.
72. Herrmann CH, Carroll RG, Wei P, Jones KA, Rice AP. Tatassociated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. J Virol 1998; 72: 9881-8.
73. Garriga J, Peng JM, Parreno M, Price DH, Henderson EE, Grana X. Upregulation of cyclin T1/CDK9 complexes during T cell activation. Oncogene 1998; 17: 3093-102.
74. Ghose R, Liou LY, Herrmann CH, Rice AP. Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines. J Virol 2001; 75: 11336-43.
75. Leucci E, De Falco G, Onnis A, et al. The role of the Cdk9/cyclin T1 complex in T cell differentiation. J Cell Physiol 2007; 212: 411-5.
76. Ramakrishnan R, Dow EC, Rice AP. Characterization of Cdk9 Tloop phosphorylation in resting and activated CD4(+) T lymphocytes. J Leukoc Biol 2009; 86: 1345-50.
77. De Falco G, Leucci E, Onnis A, et al. Cdk9/Cyclin T1 complex: A key player during the activation/differentiation process of normal lymphoid B cells. J Cell Physiol 2008; 215: 276-82.
78. Liou LY, Herrmann CH, Rice AP. Transient induction of cyclin T1 during human macrophage differentiation regulates human immunodeficiency virus type 1 Tat transactivation function. J Virol 2002; 76: 10579-87.
79. Smallie T, Ricchetti G, Horwood NJ, Feldmann M, Clark AR, Williams LM. IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. J Exp Med 2010; 207: 2081-8.
80. Haque A, Koide N, Iftakhar-E-Khuda, et al. Flavopiridol inhibits lipopolysaccharide-induced TNF-alpha production through inactivation of nuclear factor-kappa B and mitogen-activated protein kinases in the MyD88-dependent pathway. Microbiol Immunol 2011; 55: 160-7.
81. Takada Y, Aggarwal BB. Flavopiridol inhibits NF-kappa B activation induced by various carcinogens and inflammatory agents through inhibition of I kappa B alpha kinase and p65 phosphorylation-Abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004; 279: 4750-9.
82. Nowak DE, Tian B, Jamaluddin M, et al. RelA Ser(276) phosphorylation is required for activation of a subset of NF-kappa B-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol Cell Biol 2008; 28: 3623-38.
83. Takada Y, Aggarwal BB. Flavopiridol inhibits NF-kappa B activation induced by various carcinogens and inflammatory agents through inhibition of I kappa B alpha kinase and p65 phosphorylation-Abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004; 279: 4750-9.
84. Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 Coactivates Transcriptional Activation of NF-kappa B via Specific Binding to Acetylated RelA. Mol Cell Biol 2009; 29: 1375-87.
85. Giraud S, Hurlstone A, Avril S, Coqueret O. Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene. Oncogene 2004; 23: 7391-8.
86. Hou T, Ray S, Brasier AR. The functional role of an interleukin 6-inducible CDK9. STAT3 complex in human gamma-fibrinogen gene expression. J Biol Chem 2007; 282: 37091-102.
87. MacLachlan TK, Sang NL, De Luca A, Puri PL, Levrero M, Giordano A. Binding of CDK9 to TRAF2. J Cell Biochem 1998; 71: 467-78.
88. De Falco G, Neri LM, De Falco M, et al. Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines. Oncogene 2002; 21: 7464-70.